Evidence map›Paper›PMID 26709231›Full record

ReviewDevelopmental and comparative immunology2016

Development and differentiation of the erythroid lineage in mammals.

Jeffrey Barminko, Brad Reinholt, Margaret H Baron

Open access · greenAbstract readReview
In one paragraph

Review in Developmental and comparative immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Frontiers in immunology · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Reticulocyte Maturation.Membranes · 2022
    Review
  9. Article
  10. A systems pharmacology model for gene therapy in sickle cell disease.CPT: pharmacometrics & systems pharmacology · 2021
    Article
  11. Hematopoietic stem cell stretches and moves in its bone marrow niche.Critical reviews in oncology/hematology · 2021
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jeffrey BarminkoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Brad ReinholtDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Margaret H BaronDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of The Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: margaret.baron@mssm.edu.
Icahn School of Medicine at Mount Sinai · US

Funding

Induction and Specification of Hematopoietic MesodermR01HL062248 · NHLBI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BARON, MARGARET H · 2000 to 2016
$5.5M
Regulation of Erythropoiesis by the VDR Nuclear Receptor Transcription FactorR01DK102945 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BARON, MARGARET H · 2015 to 2022
$4.0M
Research Training Program in Molecular and Cellular HematologyT32HL094283 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BARON, MARGARET H · 2009 to 2013
$908k
NHLBI NIH HHS NIH RO1 HL62248NHLBI NIH HHS R01 HL062248NHLBI NIH HHS T32 HL094283NIDDK NIH HHS NIH RO1 DK102945NIDDK NIH HHS R01 DK102945
6 · The paper itself

Abstract

The red blood cell (RBC) is responsible for performing the highly specialized function of oxygen transport, making it essential for survival during gestation and postnatal life. Establishment of sufficient RBC numbers, therefore, has evolved to be a major priority of the postimplantation embryo. The "primitive" erythroid lineage is the first to be specified in the developing embryo proper. Significant resources are dedicated to producing RBCs throughout gestation. Two transient and morphologically distinct waves of hematopoietic progenitor-derived erythropoiesis are observed in development before hematopoietic stem cells (HSCs) take over to produce "definitive" RBCs in the fetal liver. Toward the end of gestation, HSCs migrate to the bone marrow, which becomes the primary site of RBC production in the adult. Erythropoiesis is regulated at various stages of erythroid cell maturation to ensure sufficient production of RBCs in response to physiological demands. Here, we highlight key aspects of mammalian erythroid development and maturation as well as differences among the primitive and definitive erythroid cell lineages.

Indexed as

Cell DifferentiationErythropoiesisAnimalsEmbryo, MammalianEmbryonic DevelopmentErythroid CellsHematopoietic Stem CellsHumansIntercellular Signaling Peptides and ProteinsYolk SacIntercellular Signaling Peptides and ProteinsEmbryoErythropoiesisHematopoiesisMammalProgenitor

Identifiers

PMID26709231
PMCPMC4775370
OpenAlexW2212457718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.